OP
BBIO icon

ORG Partners’s BridgeBio Pharma BBIO Stock Holding History

ORG Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.4K Buy
136
+58
+74% +$3.81K ﹤0.01% 993
2025
Q3 		$4.05K Buy
78
+10
+15% +$488 ﹤0.01% 1179
2025
Q2 		$2.91K Hold
68
– – ﹤0.01% 1160
2025
Q1 		$2.24K Buy
+68
New +$2.29K ﹤0.01% 1064

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ORG Partners's BBIO Position: Q4 2025 in Review

ORG Partners increased its BridgeBio Pharma (BBIO) stake by 74% in Q4 2025, buying an estimated $3.81K and bringing the position to 136 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #993.

ORG Partners first reported a position in BBIO in Q1 2025 and has held it in 4 quarters since. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • ORG Partners held 136 shares of BridgeBio Pharma worth $10.4K as of Q4 2025.
  • ORG Partners bought 58 BridgeBio Pharma shares in Q4 2025, an estimated $3.81K.
  • BridgeBio Pharma made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #993 holding.
  • ORG Partners first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 4 quarters since.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.